Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
Open Access
- 28 April 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (9), 1406-1414
- https://doi.org/10.1038/sj.bjc.6605019
Abstract
Chordomas are radio- and chemo-resistant tumours and metastasise in as many as 40% of patients. The aim of this study was to identify potential molecular targets for the treatment of chordoma. In view of the reported association of chordoma and tuberous sclerosis complex syndrome, and the available therapeutic agents against molecules in the PI3K/AKT/TSC1/TSC2/mTOR pathway, a tissue microarray of 50 chordoma cases was analysed for expression of active molecules involved in this signalling pathway by immunohistochemistry and a selected number by western blot analysis. Chordomas were positive for p-AKT (92%), p-TSC2 (96%), p-mTOR (27%), total mTOR (75%), p-p70S6K (62%), p-RPS6 (22%), p-4E-BP1 (96%) and eIF-4E (98%). Phosphatase and tensin homologue deleted on chromosome 10 expression was lost in 16% of cases. Mutations failed to be identified in PI3KCA and RHEB1 in the 23 cases for which genomic DNA was available. Fluorescence in situ hybridisation analysis for mTOR and RPS6 loci showed that 11 of 33 and 21 of 44 tumours had loss of one copy of the respective genes, results which correlated with the loss of the relevant total proteins. Fluorescence in situ hybridisation analysis for loci containing TSC1 and TSC2 revealed that all cases analysed harboured two copies of the respective genes. On the basis of p-mTOR and or p-p70S6K expression there is evidence indicating that 65% of the chordomas studied may be responsive to mTOR inhibitors, rapamycin or its analogues, and that patients may benefit from combined therapy including drugs that inhibit AKT.Keywords
This publication has 45 references indexed in Scilit:
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2PLoS Biology, 2009
- Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisationBritish Journal of Cancer, 2007
- Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activityGenes & Development, 2006
- Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathwayClinical & Experimental Metastasis, 2006
- TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activityProceedings of the National Academy of Sciences of the United States of America, 2006
- Analysis of mTOR signaling by the small G‐proteins, Rheb and RhebL1FEBS Letters, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Biochemical and Functional Characterizations of Small GTPase Rheb and TSC2 GAP ActivityMolecular and Cellular Biology, 2004
- Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinasesThe EMBO Journal, 2004
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002